Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia.
Immune activation
Neutrophils
Thrombus
Vaccine-induced immune thrombotic thrombocytopenia
Journal
European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263
Informations de publication
Date de publication:
14 10 2021
14 10 2021
Historique:
received:
09
06
2021
revised:
25
06
2021
accepted:
06
08
2021
pubmed:
19
8
2021
medline:
21
10
2021
entrez:
18
8
2021
Statut:
ppublish
Résumé
We recently reported five cases of vaccine-induced immune thrombotic thrombocytopenia (VITT) 7-10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against corona virus disease 2019 (COVID-19). We aimed to investigate the pathogenic immunological responses operating in these patients. We assessed circulating inflammatory markers by immune assays and immune cell phenotyping by flow cytometry analyses and performed immunoprecipitation with anti-platelet factor (PF)4 antibody in plasma samples followed by mass spectrometry from all five patients. A thrombus was retrieved from the sinus sagittal superior of one patient and analysed by immunohistochemistry and flow cytometry. Precipitated immune complexes revealed multiple innate immune pathway triggers for platelet and leucocyte activation. Plasma contained increased levels of innate immune response cytokines and markers of systemic inflammation, extensive degranulation of neutrophils, and tissue and endothelial damage. Blood analyses showed activation of neutrophils and increased levels of circulating H3Cit, dsDNA, and myeloperoxidase-DNA complex. The thrombus had extensive infiltration of neutrophils, formation of neutrophil extracellular traps (NETs), and IgG deposits. The results show that anti-PF4/polyanion IgG-mediated thrombus formation in VITT patients is accompanied by a massive innate immune activation and particularly the fulminant activation of neutrophils including NETosis. These results provide novel data on the immune response in this rare adenoviral vector-induced VITT.
Identifiants
pubmed: 34405870
pii: 6354117
doi: 10.1093/eurheartj/ehab506
pmc: PMC8385969
doi:
Substances chimiques
Antigen-Antibody Complex
0
COVID-19 Vaccines
0
Vaccines
0
ChAdOx1 nCoV-19
B5S3K2V0G8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4064-4072Subventions
Organisme : South-Eastern Norway Regional Health Authority
ID : 2021071
Organisme : Core Facilities program
Organisme : National network of Advanced Proteomics Infrastructure (NAPI)-the Research Council of Norway (RCN)
ID : 295910
Organisme : RCN Covid
ID : 312693
Organisme : KG Jebsen Foundation
ID : 19
Organisme : Coalition for Epidemic Preparedness Innovations (CEPI); and the University of Oslo and Oslo University Hospital
Organisme : South-Eastern Norway Regional Health Authority
Organisme : National network of Advanced Proteomics Infrastructure
Organisme : Research Council of Norway
ID : 295910
Organisme : University of Oslo
Organisme : Oslo University Hospital
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.